ERBB2 and breast cancer: The phase III KATHERINE trial (NCT01772472) demonstrated the clinical benefit of T‐DM1 after neoadjuvant therapy for HER2+ BC, regardless of prior anthracycline‐ or nonanthracycline‐based chemotherapy [572].